Chargement en cours...
ACTR-51. CLINICAL EVALUATION OF THE IMIPRIDONE ONC201 IN RECURRENT GLIOBLASTOMA: PREDICTIVE AND PHARMACODYNAMIC BIOMARKER ANALYSES
The imipridone ONC201 is the first selective antagonist of the G protein-coupled receptor DRD2 for clinical oncology. ONC201 induces p53-independent apoptosis in newly diagnosed and recurrent glioblastoma in vitro, ex vivo, and in vivo. We performed a Phase II clinical trial that enrolled an initial...
Enregistré dans:
| Publié dans: | Neuro Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693062/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.042 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|